For the quarter ending 2026-03-31, INCY had $363,281K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 1,272,676 | 1,506,835 | 1,365,980 | 1,215,529 |
| Cost of sales (including definite-lived intangible amortization) | 104,523 | 121,175 | 99,001 | 78,766 |
| Contract dispute settlement | - | 0 | 0 | 242,251 |
| Research and development - internal | 260,176 | 269,559 | 250,140 | 236,686 |
| Research and development - external | 243,127 | 272,389 | 256,344 | 245,681 |
| Other research and development | 12,600 | 69,424 | 100 | 12,550 |
| Sales and marketing | 259,563 | 308,489 | 272,302 | 256,311 |
| General and administrative | 68,524 | 81,923 | 56,779 | 74,711 |
| Asset impairment | - | 76,275 | - | - |
| Asset impairment and related disposal costs | 23,214 | - | - | - |
| (gain) loss on change in fair value of acquisition-related contingent consideration | -168 | -28,258 | -12,204 | 22,761 |
| (profit) and loss sharing under collaboration agreements | - | 0 | 0 | 0 |
| Other segment items | -2,213 | 36,580 | 19,349 | 125,315 |
| Net income | 303,330 | 299,279 | 424,169 | 404,999 |
| Depreciation and amortization | 23,802 | 23,982 | 24,023 | 22,919 |
| Stock-based compensation | 64,126 | 62,157 | 61,598 | 64,609 |
| Deferred income taxes | 63,416 | -13,497 | -124,117 | -110,071 |
| Other, net | -12,772 | -11,412 | -6,665 | 8,512 |
| (gain) loss on equity investments | 6,591 | 18,246 | 8,558 | -4,151 |
| (gain) loss on change in fair value of acquisition-related contingent consideration | -168 | -28,258 | -12,204 | 22,761 |
| Asset impairment | - | 76,275 | - | - |
| Accounts receivable | 27,027 | 128,497 | 53,001 | 20,229 |
| Prepaid expenses and other assets | -9,193 | -65,038 | 72,835 | 86,395 |
| Inventory | 12,226 | 4,859 | 5,555 | 19,525 |
| Accounts payable | 23,449 | 32,976 | -44,166 | 19,911 |
| Accrued and other liabilities | -84,725 | 138,545 | 115,136 | -476,725 |
| Net cash provided by operating activities | 369,351 | 543,301 | 559,389 | 44,741 |
| Purchase of long term investments | - | 7,875 | - | - |
| Sale of equity investments | 0 | 0 | 1 | -1 |
| Capital expenditures | 10,200 | 21,877 | 14,747 | 19,074 |
| Payments for intangible assets | 5,000 | 0 | 25,000 | 0 |
| Purchases of marketable securities | 142,703 | 82,655 | 115,506 | 56,110 |
| Maturities of marketable securities | 69,700 | 74,988 | 107,836 | 56,313 |
| Net cash (used in) provided by investing activities | -88,203 | -37,419 | -47,416 | -18,872 |
| Repurchase of common stock | - | 0 | 0 | 0 |
| Excise tax paid on repurchase of common stock | - | 0 | 0 | 19,100 |
| Proceeds from issuance of common stock under stock plans | 97,925 | 160,209 | 43,430 | 14,884 |
| Tax withholdings related to restricted and performance share vesting | 6,956 | 16,349 | 50,103 | 912 |
| Payment of finance lease liabilities | 1,184 | 1,158 | 1,141 | 1,155 |
| Payment of contingent consideration | 4,963 | 4,963 | 4,964 | 10,334 |
| Net cash provided by (used in) financing activities | 84,822 | 137,739 | -12,778 | -11,246 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | -2,689 | -801 | 841 | -1,197 |
| Net increase in cash, cash equivalents, and restricted cash | 363,281 | 642,820 | 500,036 | 13,426 |
| Cash, cash equivalents, and restricted cash at beginning of period | 3,099,669 | 2,456,849 | 1,956,813 | 1,943,387 |
| Cash, cash equivalents, and restricted cash at end of period | 3,462,950 | 3,099,669 | 2,456,849 | 1,956,813 |
INCYTE CORP (INCY)
INCYTE CORP (INCY)